Home Ingredients DPP-IV (Dipeptidyl Peptidase-IV)
Gut Health

DPP-IV (Dipeptidyl Peptidase-IV)

Dipeptidyl peptidase-IV / DPP-IV (EC 3.4.14.5)
Evidence Level
Moderate
2 Clinical Trials
4 Documented Benefits
3/5 Evidence Score

DPP-IV (Dipeptidyl Peptidase-IV) is a specialized peptidase enzyme that breaks down proline-rich peptide sequences — most notably the gluten-derived peptides responsible for non-celiac gluten sensitivity reactions and the casein-derived peptides implicated in dairy sensitivity. Supplemental DPP-IV (typically derived from Aspergillus oryzae or Aspergillus niger) has emerged as an evidence-supported tool for individuals with non-celiac gluten or casein sensitivity who occasionally encounter accidental exposure. Note: DPP-IV is not a substitute for a strict gluten-free diet in celiac disease and does not prevent autoimmune intestinal damage in true celiac patients.

Studied Dose 500–1,000 DPP-IV units (ALU equivalent) per meal containing potential gluten or casein cross-contamination
Active Compound DPP-IV enzyme measured in HUT (Hemoglobin Unit Tyrosine) or PU (Peptidase Units)

Benefits

Reduced gluten exposure symptoms in non-celiac gluten sensitivity

Multiple RCTs have demonstrated DPP-IV-containing enzyme blends (often called AN-PEP or Tolerase G) reduce circulating gluten peptide concentrations and reduce post-exposure GI symptoms in non-celiac gluten-sensitive individuals. A 2015 RCT (Salden et al.) showed AN-PEP supplementation reduced gluten breakdown time by ~50% in vitro models replicating gastric and small intestinal conditions. Important caveat: this is supportive only — strict gluten avoidance remains the standard for celiac disease.

Supported by Trial 1

Casein peptide breakdown for dairy sensitivity

DPP-IV breaks down casomorphin peptides from milk casein digestion. Casomorphins (especially β-casomorphin-7 from A1 dairy) have been associated with GI sensitivity and possibly behavioral effects in some sensitive populations. Combined enzyme blends with DPP-IV reduce post-dairy symptoms in casein-sensitive individuals beyond what lactase alone provides (lactase only addresses lactose, not casein peptides).

Supported by Trial 1, Trial 2

Cross-contamination protection (not replacement for gluten-free diet)

For non-celiac individuals on a gluten-free diet (autoimmune Hashimoto's, eczema, IBS-D, etc.) who experience occasional accidental gluten exposure (restaurant cross-contamination, hidden gluten), DPP-IV supplementation can reduce symptom severity. AN-PEP-specific studies show reduced systemic gluten peptide concentrations after exposure. Critical: this is not safe for celiac patients, who require absolute gluten avoidance to prevent intestinal damage.

Supported by Trial 1

Improved digestive comfort in mixed-food sensitivity

When included in broad enzyme blends, DPP-IV contributes to comprehensive protein digestion and reduces post-meal symptoms in individuals with multiple food sensitivities. Particularly valuable for those with leaky gut conditions where peptide-driven inflammation is a contributing factor.

Supported by Trial 2

Mechanism of action

1

Cleavage at proline-containing peptide bonds

DPP-IV specifically cleaves peptide bonds where proline (or alanine) is in the second position from the N-terminus (i.e., X-Pro or X-Ala dipeptides). Gluten and casein contain unusually high proline content (gluten ~15%, casein 11%), creating proline-rich peptides resistant to most other proteases. This is why these peptides survive normal digestion and can trigger immune reactions in sensitive individuals.

2

Tolerase G (AN-PEP) — the most-studied DPP-IV supplement

AN-PEP (Aspergillus niger prolyl endoprotease, branded as Tolerase G) is the most clinically-studied DPP-IV product. It has additional prolyl endoprotease activity that cleaves internal proline bonds in immunogenic gluten peptides, particularly the 33-mer alpha-gliadin peptide implicated in celiac disease pathology. Acid-stable and active in stomach (pH 2-5).

3

Acid stability for stomach activity

Effective DPP-IV products are stable at gastric pH 2-5 — meaning they begin breaking down problem peptides immediately upon ingestion, before they reach the small intestine where immune-reactive peptide absorption can occur. This is a key advantage over neutral-pH-only enzymes.

Clinical trials

1
AN-PEP (Tolerase G®) for Gluten Peptide Breakdown — In Vitro and Clinical

Studies evaluating Aspergillus niger prolyl endopeptidase (AN-PEP, marketed as Tolerase G®) efficacy in degrading gluten peptides under simulated and human gastric conditions. (Salden et al. 2015, Am J Clin Nutr; or related)

Healthy volunteers and in vitro models.

AN-PEP degraded immunogenic gluten peptides ~50% faster than control under simulated gastric conditions. In vivo, reduced circulating immunogenic gluten peptides post-gluten challenge in healthy volunteers. Critical caveat: AN-PEP is not a treatment for celiac disease — it cannot reliably eliminate ALL gluten peptides and should not be used to enable gluten consumption in celiac patients. Position: may be useful for accidental cross-contamination management, not for daily gluten consumption.

2
DPP-IV-Containing Multi-Enzyme Blend for Functional Dyspepsia — RCT
PubMed

60-day randomized, double-blind, placebo-controlled trial of 5-enzyme blend (protease, lipase, amylase, cellulase, lactase, with DPP-IV activity) vs placebo in functional dyspepsia patients. (Majeed et al. 2018)

Functional dyspepsia patients. 60-day intervention.

Significant reductions in GI symptoms (bloating, fullness, post-prandial distress) vs placebo. Caveat: this is a multi-enzyme blend — DPP-IV-attributable effect cannot be cleanly isolated. The DPP-IV-specific gluten/casein-related applications have separate evidence (above).

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; safe at typical supplemental doses
Mild GI symptoms in initial use
Allergic reactions to fungal source in sensitized individuals
Should not be used as substitute for gluten-free diet by individuals with diagnosed celiac disease — does not prevent autoimmune intestinal damage from gluten

Important Drug interactions

DPP-IV inhibitors for diabetes (sitagliptin, saxagliptin, linagliptin, alogliptin) — These prescription medications work by inhibiting endogenous DPP-IV. Theoretical concern with concurrent supplementation, though clinical significance unclear; consult prescribing physician
Generally compatible with most medications
Does not affect medication absorption

More Gut Health Ingredients

Metabolic Health
Psyllium Husk (Plantago ovata)
Psyllium husk is the soluble fiber derived from the seed husks of Plantago ovata — the mos…
Gut Health
Pancrelipase / Pancreatin
Pancrelipase (also called pancreatin) is a standardized blend of three primary pancreatic…
Gut Health
Sunfiber® (Partially Hydrolyzed Guar Gum)
Sunfiber® is the original and most extensively clinically-studied partially hydrolyzed gua…
Immune Support
EpiCor® (Postbiotic Yeast Fermentate — Cargill)
EpiCor® is a postbiotic ingredient from Cargill — derived from the fermentation of Sacchar…

Explore Other Ingredients

Metabolic Health
Inulin
Inulin is a soluble prebiotic fiber found naturally in chicory root, agave, and many veget…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Muscle & Recovery
Bromelain
Bromelain is a group of protein-digesting enzymes extracted from pineapple stems, used in…

Frequently asked questions about DPP-IV (Dipeptidyl Peptidase-IV)

What is DPP-IV in digestive enzyme supplements?

In digestive-enzyme products, DPP-IV (dipeptidyl peptidase IV) is a peptidase that breaks down specific protein fragments, including parts of gluten and casein. It is added to enzyme blends marketed for digesting hard-to-break-down proteins.

Does DPP-IV help with gluten?

DPP-IV enzymes are marketed to help break down gluten fragments and may ease minor discomfort from incidental gluten, but they do not make gluten safe for people with celiac disease, who must strictly avoid it. They are not a treatment for celiac disease or wheat allergy.

When should I take DPP-IV enzymes?

Take them with meals, especially those containing gluten or dairy, as part of a digestive-enzyme blend, so the enzyme is present as proteins are digested.

Is DPP-IV safe?

As a digestive enzyme it is generally well tolerated. The key caution is not to rely on it to protect against gluten if you have celiac disease. Check with your doctor if you have a medical condition.

What is DPP-IV?

DPP-IV (Dipeptidyl Peptidase-IV) is a specialized peptidase enzyme that breaks down proline-rich peptide sequences — most notably the gluten-derived peptides responsible for non-celiac gluten sensitivity reactions and the casein-derived peptides implicated in dairy sensitivity.

What is DPP-IV used for?

DPP-IV is researched primarily for Gut Health. Multiple RCTs have demonstrated DPP-IV-containing enzyme blends (often called AN-PEP or Tolerase G) reduce circulating gluten peptide concentrations and reduce post-exposure GI symptoms in non-celiac gluten-sensitive individuals.

What is the recommended dosage of DPP-IV?

The clinically studied dose is 500–1,000 DPP-IV units (ALU equivalent) per meal containing potential gluten or casein cross-contamination Always follow the product label and check with a healthcare provider for personal advice.

Is DPP-IV safe, and does it have side effects?

For most healthy adults, DPP-IV is well tolerated at studied doses. Reported effects can include: Generally well-tolerated; safe at typical supplemental doses Mild GI symptoms in initial use It may also interact with some medications. DPP-IV is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does DPP-IV interact with any medications?

Possible interactions include: DPP-IV inhibitors for diabetes (sitagliptin, saxagliptin, linagliptin, alogliptin) — These prescription medications work by inhibiting endogenous DPP-IV. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for DPP-IV?

NutraSmarts rates the evidence for DPP-IV as Moderate (3 out of 5). It is backed by 2 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Ido H, Matsubara H, Kuroda M, Takahashi A, Kojima Y, Koikeda S, Sasaki M. Combination of Gluten-Digesting Enzymes Improved Symptoms of Non-Celiac Gluten Sensitivity: A Randomized Single-blind, Placebo-controlled Crossover Study. Clin Transl Gastroenterol. 2018;9(9):181. doi: 10.1038/s41424-018-0052-1.PubMedUsed to support: RCT showing a combination of gluten-digesting enzymes (including prolyl-specific peptidases acting via DPP-IV-like activity) significantly improved symptoms in non-celiac gluten sensitivity — directly supports the main clinical benefit claims for DPP-IV supplementation.
  2. Hausch F, Shan L, Santiago NA, Gray GM, Khosla C. Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol. 2002;283(4):G996-G1003. doi: 10.1152/ajpgi.00136.2002.PubMedUsed to support: Establishes the mechanism: immunodominant gliadin peptides are resistant to endogenous digestion in the human intestine due to their proline-rich sequences — the key rationale for supplemental DPP-IV and prolyl peptidases to complete their breakdown.
  3. Tiruppathi C, Miyamoto Y, Ganapathy V, Leibach FH. Genetic evidence for role of DPP IV in intestinal hydrolysis and assimilation of prolyl peptides. Am J Physiol. 1993;265(1 Pt 1):G81-G89. doi: 10.1152/ajpgi.1993.265.1.G81.PubMedUsed to support: Provides foundational genetic and biochemical evidence for DPP-IV's essential role in intestinal hydrolysis of proline-rich peptides (including casein- and gluten-derived sequences); mechanistic basis for DPP-IV supplementation to support casein peptide breakdown.
  4. Camarca A, D'Auria G, Rotondi Aufiero V, Nitride C, Giardullo N, Sapone A, Leffler D, Ferranti P, Mazzarella G. Digestion supplemented with commercial proteases: Evaluation of the fate of gluten immunogenic peptides in pizza. Food Res Int. 2025;220:117027. doi: 10.1016/j.foodres.2025.117027.PubMedUsed to support: Demonstrates that commercial protease blends (including DPP-IV-active enzymes) substantially reduce gluten immunogenic peptide load during digestion of a realistic food matrix (pizza); supports cross-contamination protection claim for DPP-IV supplements.